Publicacions en col·laboració amb investigadors/es de Hospital Universitario 12 de Octubre (14)

2024

  1. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

    Nature Medicine, Vol. 30, Núm. 1, pp. 271-278

  2. Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence

    Future Oncology, Vol. 20, Núm. 20, pp. 1401-1413

2023

  1. Young oncologists’ perspective on the role and future of the clinician-scientist in oncology

    ESMO Open

2022

  1. SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA

    Future Oncology, Vol. 18, Núm. 34, pp. 3791-3800

2021

  1. First-In-Human Phase I Study of a Next-Generation, Oral, TGFb Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

    Clinical Cancer Research, Vol. 27, Núm. 24, pp. 6666-6676

2019

  1. Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer

    ESMO Open, Vol. 4, Núm. 4

2018

  1. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer

    Investigational New Drugs, Vol. 36, Núm. 5, pp. 848-859

2017

  1. Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial

    Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 227-235

  2. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

    European Journal of Cancer, Vol. 82, pp. 16-24

2011

  1. A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors

    Clinical Cancer Research, Vol. 17, Núm. 19, pp. 6313-6321

2010

  1. Advanced ovarian cancer: Phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel

    Journal of the National Cancer Institute, Vol. 102, Núm. 20, pp. 1547-1556

2007

  1. Treatment guidelines in ovarian cancer

    Clinical and Translational Oncology, Vol. 9, Núm. 5, pp. 308-316

2005

  1. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer

    Journal of Clinical Oncology, Vol. 23, Núm. 34, pp. 8636-8645

2003

  1. Doxurubicin versus doxorubicin and cisplatin in endometrial carcinoma: Definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

    Annals of Oncology, Vol. 14, Núm. 3, pp. 441-448